

March 2, 2009
AnGes MG, Inc.

AnGes Reached a Broad Agreement with the FDA on the Clinical Trial Designs for Their
Phase III Study with Collategene™

In the recent meeting with the FDA (February 26, 2009), AnGes Inc. (AnGes), the US subsidiary of AnGes MG, Inc. reached a broad agreement with the FDA on the clinical trial designs for their Phase III study with Collategene™.

During this meeting with the FDA, it was agreed that critical limb ischemia (CLI) patients with either no option for revascularization or a high risk for surgical revascularization will be enrolled in the studies. This is in line with AnGes' proposed study design, and by including broader patient population, we expect to achieve a higher enrollment rate in the forthcoming phase III study.